nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—peripheral nervous system neoplasm	0.417	1	CbGaD
Dabigatran etexilate—UGT2B7—Epirubicin—peripheral nervous system neoplasm	0.136	0.412	CbGbCtD
Dabigatran etexilate—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0463	0.141	CbGbCtD
Dabigatran etexilate—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0463	0.141	CbGbCtD
Dabigatran etexilate—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0321	0.0976	CbGbCtD
Dabigatran etexilate—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0198	0.0601	CbGbCtD
Dabigatran etexilate—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0184	0.056	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0181	0.0551	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0124	0.0375	CbGbCtD
Dabigatran etexilate—CES2—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00346	0.149	CbGpPWpGaD
Dabigatran etexilate—CES1—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00204	0.0877	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00138	0.0594	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000951	0.0409	CbGpPWpGaD
Dabigatran etexilate—F2—Intrinsic Pathway—KNG1—peripheral nervous system neoplasm	0.000768	0.033	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—CD55—peripheral nervous system neoplasm	0.000744	0.032	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—NF1—peripheral nervous system neoplasm	0.000713	0.0307	CbGpPWpGaD
Dabigatran etexilate—F2—Formation of Fibrin Clot (Clotting Cascade)—KNG1—peripheral nervous system neoplasm	0.000518	0.0223	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000506	0.0218	CbGpPWpGaD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000427	0.0184	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000407	0.0175	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000388	0.0167	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00037	0.0159	CbGpPWpGaD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—KNG1—peripheral nervous system neoplasm	0.000349	0.015	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.000333	0.0143	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000308	0.0133	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000304	0.0131	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000298	0.0128	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000276	0.0119	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000276	0.0119	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.000252	0.0108	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—PTPN11—peripheral nervous system neoplasm	0.000242	0.0104	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00024	0.0103	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000236	0.0102	CbGpPWpGaD
Dabigatran etexilate—CES1—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000228	0.00983	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.000219	0.000949	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000219	0.000948	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000947	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000947	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000947	CcSEcCtD
Dabigatran etexilate—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000217	0.000941	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000217	0.000939	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000217	0.000939	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.000937	CcSEcCtD
Dabigatran etexilate—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000216	0.000936	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000216	0.000934	CcSEcCtD
Dabigatran etexilate—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000214	0.000929	CcSEcCtD
Dabigatran etexilate—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000214	0.000929	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.000919	CcSEcCtD
Dabigatran etexilate—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.000917	CcSEcCtD
Dabigatran etexilate—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00021	0.00091	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000209	0.000907	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000209	0.000907	CcSEcCtD
Dabigatran etexilate—Infection—Cisplatin—peripheral nervous system neoplasm	0.000208	0.000901	CcSEcCtD
Dabigatran etexilate—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000208	0.0009	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000898	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000206	0.000895	CcSEcCtD
Dabigatran etexilate—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000206	0.000893	CcSEcCtD
Dabigatran etexilate—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000206	0.000893	CcSEcCtD
Dabigatran etexilate—Rash—Topotecan—peripheral nervous system neoplasm	0.000206	0.000892	CcSEcCtD
Dabigatran etexilate—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000206	0.000892	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000205	0.000889	CcSEcCtD
Dabigatran etexilate—Cough—Etoposide—peripheral nervous system neoplasm	0.000205	0.000888	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000205	0.000888	CcSEcCtD
Dabigatran etexilate—Headache—Topotecan—peripheral nervous system neoplasm	0.000205	0.000887	CcSEcCtD
Dabigatran etexilate—Rash—Tretinoin—peripheral nervous system neoplasm	0.000204	0.000885	CcSEcCtD
Dabigatran etexilate—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000204	0.000885	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000204	0.000885	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000204	0.00879	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000204	0.000885	CcSEcCtD
Dabigatran etexilate—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000204	0.000885	CcSEcCtD
Dabigatran etexilate—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000204	0.000884	CcSEcCtD
Dabigatran etexilate—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000203	0.000881	CcSEcCtD
Dabigatran etexilate—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000203	0.000881	CcSEcCtD
Dabigatran etexilate—Headache—Tretinoin—peripheral nervous system neoplasm	0.000203	0.00088	CcSEcCtD
Dabigatran etexilate—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000203	0.00088	CcSEcCtD
Dabigatran etexilate—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000203	0.000879	CcSEcCtD
Dabigatran etexilate—Constipation—Vincristine—peripheral nervous system neoplasm	0.000202	0.000877	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000877	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000877	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000877	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000202	0.000875	CcSEcCtD
Dabigatran etexilate—Rash—Melphalan—peripheral nervous system neoplasm	0.000202	0.000874	CcSEcCtD
Dabigatran etexilate—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000202	0.000873	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000201	0.00087	CcSEcCtD
Dabigatran etexilate—Chest pain—Etoposide—peripheral nervous system neoplasm	0.0002	0.000867	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.0002	0.000865	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000199	0.000861	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000197	0.000853	CcSEcCtD
Dabigatran etexilate—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000196	0.000847	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000847	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000195	0.000846	CcSEcCtD
Dabigatran etexilate—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000195	0.000845	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000194	0.000841	CcSEcCtD
Dabigatran etexilate—Nausea—Topotecan—peripheral nervous system neoplasm	0.000194	0.000841	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000194	0.000839	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000838	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000836	CcSEcCtD
Dabigatran etexilate—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000193	0.000834	CcSEcCtD
Dabigatran etexilate—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000193	0.000834	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000192	0.000831	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000191	0.000826	CcSEcCtD
Dabigatran etexilate—Infection—Etoposide—peripheral nervous system neoplasm	0.00019	0.000825	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00019	0.000823	CcSEcCtD
Dabigatran etexilate—Nausea—Melphalan—peripheral nervous system neoplasm	0.00019	0.000823	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000819	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000189	0.000819	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000188	0.000813	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000187	0.000811	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000187	0.000809	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000187	0.000808	CcSEcCtD
Dabigatran etexilate—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000186	0.000807	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000185	0.000801	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000798	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000182	0.000789	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000182	0.000787	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000181	0.000785	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000181	0.000784	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000784	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000181	0.000783	CcSEcCtD
Dabigatran etexilate—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000179	0.000776	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000776	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.000773	CcSEcCtD
Dabigatran etexilate—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000176	0.000764	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000761	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000758	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000758	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000174	0.000755	CcSEcCtD
Dabigatran etexilate—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000174	0.000753	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—peripheral nervous system neoplasm	0.000173	0.00745	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000171	0.00737	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000171	0.000741	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000738	CcSEcCtD
Dabigatran etexilate—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00017	0.000736	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000734	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000169	0.00073	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000169	0.00073	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000168	0.00073	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000168	0.000729	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000168	0.000728	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000167	0.000724	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000166	0.000717	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000165	0.000716	CcSEcCtD
Dabigatran etexilate—Constipation—Etoposide—peripheral nervous system neoplasm	0.000164	0.00071	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000164	0.00071	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000704	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000163	0.00699	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000162	0.000704	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000162	0.000702	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000161	0.000696	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00016	0.00687	CbGpPWpGaD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000159	0.00069	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000689	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000685	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000157	0.000682	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000679	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000157	0.000679	CcSEcCtD
Dabigatran etexilate—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000157	0.000678	CcSEcCtD
Dabigatran etexilate—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000156	0.000677	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000676	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.000676	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000156	0.00669	CbGpPWpGaD
Dabigatran etexilate—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000155	0.000671	CcSEcCtD
Dabigatran etexilate—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000155	0.00067	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000154	0.000668	CcSEcCtD
Dabigatran etexilate—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000154	0.000667	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000152	0.00066	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000659	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000152	0.000657	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000152	0.000657	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000151	0.000655	CcSEcCtD
Dabigatran etexilate—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00015	0.000652	CcSEcCtD
Dabigatran etexilate—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.00015	0.000651	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000647	CcSEcCtD
Dabigatran etexilate—Rash—Vincristine—peripheral nervous system neoplasm	0.000149	0.000647	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000149	0.000646	CcSEcCtD
Dabigatran etexilate—F2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000149	0.00642	CbGpPWpGaD
Dabigatran etexilate—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000646	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000149	0.000644	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000149	0.000644	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000148	0.000642	CcSEcCtD
Dabigatran etexilate—Headache—Vincristine—peripheral nervous system neoplasm	0.000148	0.000642	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000639	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000637	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000634	CcSEcCtD
Dabigatran etexilate—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000146	0.000632	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000143	0.00062	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000141	0.000612	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000609	CcSEcCtD
Dabigatran etexilate—Nausea—Vincristine—peripheral nervous system neoplasm	0.000141	0.000609	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000608	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PTPN11—peripheral nervous system neoplasm	0.00014	0.00603	CbGpPWpGaD
Dabigatran etexilate—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000606	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC2A1—peripheral nervous system neoplasm	0.000139	0.00599	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000139	0.00596	CbGpPWpGaD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.000599	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.000597	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000138	0.000596	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.000596	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000595	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000594	CcSEcCtD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000137	0.00589	CbGpPWpGaD
Dabigatran etexilate—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000592	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000591	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000136	0.000588	CcSEcCtD
Dabigatran etexilate—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000133	0.000576	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000133	0.00571	CbGpPWpGaD
Dabigatran etexilate—Rash—Cisplatin—peripheral nervous system neoplasm	0.000132	0.000572	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000132	0.000571	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000571	CcSEcCtD
Dabigatran etexilate—UGT2B7—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000131	0.00565	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000131	0.000568	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000563	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000562	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000552	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.00055	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000127	0.000549	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000548	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000547	CcSEcCtD
Dabigatran etexilate—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000124	0.000539	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000124	0.00533	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000122	0.000528	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000528	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000527	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000121	0.00522	CbGpPWpGaD
Dabigatran etexilate—Rash—Etoposide—peripheral nervous system neoplasm	0.000121	0.000524	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000121	0.000523	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.00012	0.00518	CbGpPWpGaD
Dabigatran etexilate—Headache—Etoposide—peripheral nervous system neoplasm	0.00012	0.00052	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.00052	CcSEcCtD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.00012	0.00514	CbGpPWpGaD
Dabigatran etexilate—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000512	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000511	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000504	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000501	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—GNS—peripheral nervous system neoplasm	0.000115	0.00497	CbGpPWpGaD
Dabigatran etexilate—Cough—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000498	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—peripheral nervous system neoplasm	0.000114	0.000493	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000493	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000488	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000486	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000486	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000482	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—NME1—peripheral nervous system neoplasm	0.000111	0.00476	CbGpPWpGaD
Dabigatran etexilate—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000473	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000467	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000108	0.00463	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000466	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000464	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000463	CcSEcCtD
Dabigatran etexilate—UGT1A9—NRF2 pathway—HGF—peripheral nervous system neoplasm	0.000107	0.00459	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—COX2—peripheral nervous system neoplasm	0.000107	0.00458	CbGpPWpGaD
Dabigatran etexilate—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000461	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000458	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000457	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000456	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000456	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000452	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000104	0.00448	CbGpPWpGaD
Dabigatran etexilate—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000449	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000449	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000446	CcSEcCtD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000101	0.00435	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000101	0.00435	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000435	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	9.94e-05	0.000431	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—peripheral nervous system neoplasm	9.88e-05	0.000428	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	9.79e-05	0.000424	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—peripheral nervous system neoplasm	9.78e-05	0.000424	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	9.75e-05	0.000423	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	9.74e-05	0.000422	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	9.66e-05	0.000418	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	9.58e-05	0.000415	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	9.46e-05	0.00041	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—peripheral nervous system neoplasm	9.39e-05	0.00404	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Doxorubicin—peripheral nervous system neoplasm	9.29e-05	0.000403	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	9.28e-05	0.000402	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—peripheral nervous system neoplasm	9.27e-05	0.000401	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—peripheral nervous system neoplasm	9.19e-05	0.000398	CcSEcCtD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	9.18e-05	0.00395	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	9.06e-05	0.000393	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TP53—peripheral nervous system neoplasm	8.91e-05	0.00383	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	8.87e-05	0.000384	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	8.79e-05	0.000381	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	8.79e-05	0.00378	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	8.75e-05	0.000379	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.75e-05	0.00376	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.59e-05	0.000372	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000371	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—peripheral nervous system neoplasm	8.54e-05	0.00037	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—peripheral nervous system neoplasm	8.5e-05	0.000368	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	8.5e-05	0.000368	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—peripheral nervous system neoplasm	8.42e-05	0.00362	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	8.13e-05	0.000352	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	7.98e-05	0.00343	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	7.92e-05	0.000343	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—peripheral nervous system neoplasm	7.9e-05	0.000342	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	7.86e-05	0.000341	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000334	CcSEcCtD
Dabigatran etexilate—F2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	7.65e-05	0.00329	CbGpPWpGaD
Dabigatran etexilate—Pruritus—Epirubicin—peripheral nervous system neoplasm	7.6e-05	0.000329	CcSEcCtD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	7.53e-05	0.00324	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000319	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	7.33e-05	0.000317	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.27e-05	0.00313	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—peripheral nervous system neoplasm	7.13e-05	0.000309	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.000308	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000305	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—ENO2—peripheral nervous system neoplasm	6.99e-05	0.00301	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	6.99e-05	0.00301	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Epirubicin—peripheral nervous system neoplasm	6.83e-05	0.000296	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000295	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—peripheral nervous system neoplasm	6.78e-05	0.000294	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—peripheral nervous system neoplasm	6.77e-05	0.000293	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—IFNB1—peripheral nervous system neoplasm	6.74e-05	0.0029	CbGpPWpGaD
Dabigatran etexilate—Headache—Epirubicin—peripheral nervous system neoplasm	6.73e-05	0.000292	CcSEcCtD
Dabigatran etexilate—F2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	6.66e-05	0.00287	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000285	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—peripheral nervous system neoplasm	6.38e-05	0.000277	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—peripheral nervous system neoplasm	6.32e-05	0.000274	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—peripheral nervous system neoplasm	6.27e-05	0.000272	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	6.26e-05	0.000271	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—KNG1—peripheral nervous system neoplasm	6.25e-05	0.00269	CbGpPWpGaD
Dabigatran etexilate—Headache—Doxorubicin—peripheral nervous system neoplasm	6.23e-05	0.00027	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—peripheral nervous system neoplasm	6.16e-05	0.00265	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	6.11e-05	0.00263	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—peripheral nervous system neoplasm	6.07e-05	0.00261	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	6.05e-05	0.0026	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.91e-05	0.00254	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—BCHE—peripheral nervous system neoplasm	5.91e-05	0.00254	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—peripheral nervous system neoplasm	5.91e-05	0.000256	CcSEcCtD
Dabigatran etexilate—UGT2B15—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.64e-05	0.00243	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	5.6e-05	0.00241	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	5.58e-05	0.0024	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TH—peripheral nervous system neoplasm	5.56e-05	0.00239	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—GNAS—peripheral nervous system neoplasm	5.46e-05	0.00235	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNS—peripheral nervous system neoplasm	5.26e-05	0.00226	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HGF—peripheral nervous system neoplasm	5.2e-05	0.00224	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NME1—peripheral nervous system neoplasm	5.04e-05	0.00217	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	4.95e-05	0.00213	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.91e-05	0.00211	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—COX2—peripheral nervous system neoplasm	4.85e-05	0.00209	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	4.79e-05	0.00206	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.71e-05	0.00203	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GNAS—peripheral nervous system neoplasm	4.54e-05	0.00195	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	4.53e-05	0.00195	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.52e-05	0.00194	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	4.51e-05	0.00194	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ABCB1—peripheral nervous system neoplasm	4.45e-05	0.00192	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNS—peripheral nervous system neoplasm	4.27e-05	0.00184	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	4.18e-05	0.0018	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	4.13e-05	0.00178	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NME1—peripheral nervous system neoplasm	4.1e-05	0.00176	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.01e-05	0.00173	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	3.95e-05	0.0017	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—COX2—peripheral nervous system neoplasm	3.94e-05	0.0017	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	3.86e-05	0.00166	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PTPN11—peripheral nervous system neoplasm	3.8e-05	0.00163	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.59e-05	0.00154	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.57e-05	0.00154	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.45e-05	0.00149	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	3.31e-05	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.3e-05	0.00142	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO2—peripheral nervous system neoplasm	3.19e-05	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.14e-05	0.00135	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	2.86e-05	0.00123	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.71e-05	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—BCHE—peripheral nervous system neoplasm	2.69e-05	0.00116	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.62e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—peripheral nervous system neoplasm	2.59e-05	0.00111	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.57e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TH—peripheral nervous system neoplasm	2.53e-05	0.00109	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.48e-05	0.00107	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—peripheral nervous system neoplasm	2.28e-05	0.000982	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	2.27e-05	0.000979	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BCHE—peripheral nervous system neoplasm	2.19e-05	0.000941	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.18e-05	0.000938	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.12e-05	0.000912	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.09e-05	0.000898	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GNAS—peripheral nervous system neoplasm	2.07e-05	0.000889	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	2.06e-05	0.000888	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TH—peripheral nervous system neoplasm	2.06e-05	0.000885	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.04e-05	0.000879	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—peripheral nervous system neoplasm	2.03e-05	0.000872	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.02e-05	0.000869	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.96e-05	0.000843	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.88e-05	0.000809	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.85e-05	0.000797	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.81e-05	0.000778	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—peripheral nervous system neoplasm	1.75e-05	0.000752	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GNAS—peripheral nervous system neoplasm	1.68e-05	0.000722	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—peripheral nervous system neoplasm	1.67e-05	0.000719	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.65e-05	0.000709	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.64e-05	0.000708	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.61e-05	0.000694	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—peripheral nervous system neoplasm	1.47e-05	0.000635	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.32e-05	0.00057	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.31e-05	0.000564	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.29e-05	0.000554	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—peripheral nervous system neoplasm	1.22e-05	0.000527	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.19e-05	0.000511	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	1.12e-05	0.000481	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.02e-05	0.000438	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1e-05	0.000432	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.59e-06	0.000412	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	9.57e-06	0.000412	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	9.43e-06	0.000406	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.32e-06	0.000401	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.23e-06	0.000397	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.46e-06	0.000364	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.74e-06	0.000333	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	7.7e-06	0.000331	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.21e-06	0.00031	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—peripheral nervous system neoplasm	5.92e-06	0.000255	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.66e-06	0.000244	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—peripheral nervous system neoplasm	5.58e-06	0.00024	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5e-06	0.000215	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—peripheral nervous system neoplasm	4.53e-06	0.000195	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	2.08e-06	8.95e-05	CbGpPWpGaD
